S&P 500
5,888.55
-0.6%
-$32.99
DJI
42,098.70
-0.6%
-$244.95
NASDAQ
19,100.94
-0.5%
-$98.23
Bitcoin
107,937.00
-0.8%
-876.05
AAPL
$200.40
+0.1%
+$0.19
AMZN
$204.64
-0.7%
-$1.38
GOOG
$173.28
-0.4%
-$0.70
META
$643.48
+0.2%
+$1.16
MSFT
$457.40
-0.7%
-$3.28
NVDA
$135.14
-0.3%
-$0.36
TSLA
$356.97
-1.6%
-$5.92
Sab Biotherapeutics (NASDAQ: SABS)
$1.83
(1.1%)
$0.02
Price as of May 27, 2025, 3:55 p.m. ET
Sab Biotherapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Sab Biotherapeutics Company Info
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. It is engaged in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. SAB Biotherapeutics was founded by Eddie J. Sullivan and Christine E. Hamilton and is headquartered in Sioux Falls, SD.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.